Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface

Journal of Tissue Engineering and Regenerative Medicine

Volumn 4, Issue 4, 2010, Pages 247-258

  Balyasnikova, Irina V ^a   Franco Gou, Rosa ^b   Michael Mathis, J ^b   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Brain tumours; EGFRvIII; Mesenchymal stem cells; Single chain antibody; Surface; Targeting

Indexed keywords

ACTIVATION ANALYSIS; ANTIBODIES; CELL MEMBRANES; CELL PROLIFERATION; CHAINS; CONTROLLED DRUG DELIVERY; ENCODING (SYMBOLS); GENE THERAPY; SIGNAL ENCODING; STEM CELLS; TARGETED DRUG DELIVERY; TUMORS;

BRAIN TUMORS; CELL SURFACES; CELL-BE; CELL/B.E; CELL/BE; EGFRVIII; GENETIC MODIFICATIONS; MESENCHYMAL STEM CELL; SINGLE-CHAIN ANTIBODIES; TARGETING;

CELL CULTURE;

B7 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; EPITOPE;

ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ARTICLE; CELL POPULATION; CELL SURFACE; CONTROLLED STUDY; DNA MODIFICATION; FEASIBILITY STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; ADULT; BIOSYNTHESIS; CELL COMMUNICATION; CELL MEMBRANE; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; GENETIC PROCEDURES; GENETICS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

ADULT; ANTI-BACTERIAL AGENTS; CELL COMMUNICATION; CELL MEMBRANE; EPITOPES; FLOW CYTOMETRY; GENETIC TECHNIQUES; HUMANS; MESENCHYMAL STROMAL CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-CHAIN ANTIBODIES;

EID: 77953076008     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.228     Document Type: Article

References (33)

1. Aluigi M, Fogli M, Curti A, et al. 2006; Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24(2): 454-461. (Pubitemid 44464815)
2. Andersen DC, Reilly DE. 2004; Production technologies for monoclonal antibodies and their fragments. Curr Opin Biotechnol 15(5): 456-462. (Pubitemid 39304044)
3. Beckermann BM, Kallifatidis G, Groth A, et al. 2008; VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99(4): 622-631.
4. Bexell D, Gunnarsson S, Tormin A, et al. 2009; Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17(1): 183-190.
5. Chartrain M, Chu L. 2008; Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol 9(6): 447-467.
6. Cherry SR, Biniszkiewicz D, van Parijs L, et al. 2000; Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 20(20): 7419-7426.
7. Chou WC, Liao KW, Lo YC, et al. 1999; Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng 65(2): 160-169.
8. Compte M, Cuesta AM, Sanchez-Martin D, et al. 2009; Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 27(3): 753-760.
9. Eliopoulos N, Francois M, Boivin MN, et al. 2008; Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 68(12): 4810-4818.
10. Emrich JG, Brady LW, Quang TS, et al. 2002; Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25(6): 541-546.
11. Fox SR, Patel UA, Yap MG, et al. 2004; Maximizing interferon-γ production by Chinese hamster ovary cells through temperature shift optimization: experimental and modeling. Biotechnol Bioeng 85(2): 177-184. (Pubitemid 38141119)
12. Frederick L, Eley G, Wang XY, et al. 2000; Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2(3): 159-163.
13. Gheisari Y, Soleimani M, Azadmanesh K, et al. 2008; Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods. Cytotherapy 10(8): 815-823.
14. Harui A, Suzuki S, Kochanek S, et al. 1999; Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73(7): 6141-6146. (Pubitemid 29274908)
15. Helledie T, Nurcombe V, Cool SM. 2008; A simple and reliable electroporation method for human bone marrow mesenchymal stem cells. Stem Cells Dev 17(4): 837-848.
16. Ho M, Pastan I. 2009; Mammalian cell display for antibody engineering. Methods Mol Biol 525: 337-352 xiv.
17. Kanehira M, Xin H, Hoshino K, et al. 2007; Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 14(11): 894-903. (Pubitemid 47557220)
18. Kioi M, Seetharam S, Puri RK. 2008; Targeting IL-13Rα2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7(6): 1579-1587.
19. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res 5(6): 1539-1549.
20. Kucerova L, Matuskova M, Pastorakova A, et al. 2008; Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 10(10): 1071-1082.
21. Liao KW, Lo YC, Roffler SR. 2000; Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther 7(4): 339-347.
22. Liu F, Lu Q, Ye X, et al. 2008; Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice. Cancer Biol Ther 7(3): 448-453. (Pubitemid 351847066)
23. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, et al. 1996; Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93(25): 14815-14820. (Pubitemid 26419052)
24. Modjtahedi H, Moscatello DK, Box G, et al. 2003; Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105(2): 273-280.
25. Nakamizo A, Marini F, Amano T, et al. 2005; Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65(8): 3307-3318. (Pubitemid 40524615)
26. Nakamura K, Ito Y, Kawano Y, et al. 2004; Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11(14): 1155-1164. (Pubitemid 39117311)
27. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143-147. (Pubitemid 29282067)
28. Pittenger MF, Martin BJ. 2004; Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95(1): 9-20. (Pubitemid 38931831)
29. Sasportas LS, Kasmieh R, Wakimoto H, et al. 2009; Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106(12): 4822-4827.
30. Schatz SM, Kerschbaumer RJ, Gerstenbauer G, et al. 2003; Higher expression of Fab antibody fragments in a CHO cell line at reduced temperature. Biotechnol Bioeng 84(4): 433-438. (Pubitemid 37280213)
31. Sonabend AM, Ulasov IV, Tyler MA, et al. 2008; Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26(3): 831-841.
32. Studeny M, Marini FC, Champlin RE, et al. 2002; Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 62(13): 3603-3608. (Pubitemid 34728832)
33. Wei LH, Olafsen T, Radu C, et al. 2008; Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med 49(11): 1828-1835.